Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 10, 2013, Pages 1673-1696

  Hendriks, Wiljan J A J ^a   Pulido, Rafael ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Cell signaling; Disease susceptibility; Phosphotyrosine dephosphorylation; Post translational modification

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE;

DISEASE PREDISPOSITION; GENE FREQUENCY; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

AURKA; AURORA KINASE A; BAND 4.1/EZRIN/RADIXIN/MOESIN; CAM; CD; CELL ADHESION MOLECULE; CELL SIGNALING; CHARCOT-MARIE-TOOTH; CMT; CROHN'S DISEASE; DENSITY-ENHANCED PHOSPHATASE-1; DEP-1; DISEASE SUSCEPTIBILITY; DUAL-SPECIFICITY PTP; DUSP; EYA; EYES ABSENT; FERM; FIBRONECTIN TYPE III; FNIII; GLEPP1; GLOMERULAR EPITHELIAL PROTEIN 1; HEREDITARY HAEMORRHAGIC TELANGIECTASIA; HOLOPROSENCEPHALY; HPE; HTT; IG; IMMUNOGLOBULIN; INSULIN RECEPTOR; IR; JMML; JUVENILE MYELOMONOCYTIC LEUKEMIA; KINASE NON-CATALYTIC C-LOBE DOMAIN; KIND; MAP KINASE PHOSPHATASE; MKP; MS; MTMR; MULTIPLE SCLEROSIS; MYOTUBULARIN-RELATED PROTEIN; NOONAN SYNDROME; NS; PDZ; PHOSPHATASE AND TENSIN HOMOLOG; PHOSPHATASE OF REGENERATING LIVER; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; PHOSPHOTYROSINE DEPHOSPHORYLATION; PHTS; PI(3,4,5)P3; POST-TRANSLATIONAL MODIFICATION; PRL; PROTEIN TYROSINE PHOSPHATASE; PSD95/DLG/ZO-1; PTEN; PTEN HAMARTOMA TUMOR SYNDROMES; PTP; RA; RECEPTOR TYROSINE KINASE; RECEPTOR-TYPE PTP; RESTLESS LEGS SYNDROME; RHEUMATOID ARTHRITIS; RLS; RPTP; RTK; SCID; SEVERE COMBINED IMMUNODEFICIENCY; SFK; SH2; SINGLE NUCLEOTIDE POLYMORPHISM; SLE; SNP; SRC HOMOLOGY TYPE 2; SRC-FAMILY TYROSINE KINASE; STEP; STRIATAL-ENRICHED PTP; SYSTEMIC LUPUS ERYTHEMATOSUS; X-LINKED MYOTUBULAR MYOPATHY; XLMTM;

GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOENZYMES; PROTEIN TYROSINE PHOSPHATASES;

EID: 84879589744     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.022     Document Type: Review

References (390)

1. Lim W.A., Pawson T. Phosphotyrosine signaling: evolving a new cellular communication system. Cell 2010, 142:661-667.
2. Wilkie A.O., Patey S.J., Kan S.H., van den Ouweland A.M., Hamel B.C. FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am. J. Med. Genet. 2002, 112:266-278.
3. Hendriks W.J., Elson A., Harroch S., Stoker A.W. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. FEBS J. 2008, 275:816-830.
4. Hendriks W.J., Elson A., Harroch S., Pulido R., Stoker A., den Hertog J. Protein tyrosine phosphatases in health and disease. FEBS J. 2013, 280:708-730.
5. Tonks N.K. Protein tyrosine phosphatases: from housekeeping enzymes to master-regulators of signal transduction. FEBS J. 2013, 280:346-378.
6. Julien S.G., Dube N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. 2011, 11:35-49.
7. Navis A.C., van den Eijnden M., Schepens J.T., Hooft van Huijsduijnen R., Wesseling P., Hendriks W.J. Protein tyrosine phosphatases in glioma biology. Acta Neuropathol. 2010, 119:157-175.
8. Nunes-Xavier C., Roma-Mateo C., Rios P., Tarrega C., Cejudo-Marin R., Tabernero L., Pulido R. Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med. Chem. 2011, 11:109-132.
9. Pulido R., Hooft van Huijsduijnen R. Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. FEBS J. 2008, 275:848-866.
10. Bermudez O., Pages G., Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am. J. Physiol. 2010, 299:C189-C202.
11. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
12. Andersen J.N., Jansen P.G., Echwald S.M., Mortensen O.H., Fukada T., Del Vecchio R., Tonks N.K., Moller N.P. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 2004, 18:8-30.
13. Karagoz I.D., Ozaslan M., Cengiz B., Kalender M.E., Kilic I.H., Oztuzcu S., Gogebakan B., Demiryurek A.T. CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. Tumour Biol. 2010, 31:597-604.
14. Gloria-Bottini F., Spina C., Nicotra M., Saccucci P., Ambrosi S., Bottini E. Acid phosphatase locus 1 genetic polymorphism and cancer grading. Am. J. Med. Sci. 2012, 344:32-34.
15. Banci M., Saccucci P., D'Annibale F., Dofcaci A., Trionfera G., Magrini A., Bottini N., Bottini E., Gloria-Bottini F. ACP1 genetic polymorphism and coronary artery disease: an association study. Cardiology 2009, 113:236-242.
16. Souza A.C., Azoubel S., Queiroz K.C., Peppelenbosch M.P., Ferreira C.V. From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. Cell. Mol. Life Sci. 2009, 66:1140-1153.
17. Alho I., Clara Bicho M., Carvalho R., da Silva A.P., Costa L., Bicho M. Low molecular weight protein tyrosine phosphatase genetic polymorphism and susceptibility to cancer development. Cancer Genet. Cytogenet. 2008, 181:20-24.
18. Gloria-Bottini F., Lucarelli P., Saccucci P., Cozzoli E., Cerminara C., Curatolo P., Bottini E. Genetic polymorphism and idiopathic generalized epilepsy. Evidence of interaction between haptoglobin and ACP1 systems. Neuropediatrics 2008, 39:357-358.
19. Tsygankov A.Y. TULA-family proteins: a new class of cellular regulators. J. Cell. Physiol. 2013, 228:43-49.
20. Tiganis T. PTP1B and TCPTP-nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 2013, 280(2):445-458. (PMID: 22404968).
21. Di Paola R., Frittitta L., Miscio G., Bozzali M., Baratta R., Centra M., Spampinato D., Santagati M.G., Ercolino T., Cisternino C., Soccio T., Mastroianno S., Tassi V., Almgren P., Pizzuti A., Vigneri R., Trischitta V. A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am. J. Hum. Genet. 2002, 70:806-812.
22. Mok A., Cao H., Zinman B., Hanley A.J., Harris S.B., Kennedy B.P., Hegele R.A. A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. J. Clin. Endocrinol. Metab. 2002, 87:724-727.
23. Echwald S.M., Bach H., Vestergaard H., Richelsen B., Kristensen K., Drivsholm T., Borch-Johnsen K., Hansen T., Pedersen O. A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro. Diabetes 2002, 51:1-6.
24. Palmer N.D., Bento J.L., Mychaleckyj J.C., Langefeld C.D., Campbell J.K., Norris J.M., Haffner S.M., Bergman R.N., Bowden D.W. Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study. Diabetes 2004, 53:3013-3019. s. insulin resistance atherosclerosis study family.
25. Ukkola O., Rankinen T., Lakka T., Leon A.S., Skinner J.S., Wilmore J.H., Rao D.C., Kesaniemi Y.A., Bouchard C. Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism. Obes. Res. 2005, 13:829-834.
26. Bento J.L., Palmer N.D., Mychaleckyj J.C., Lange L.A., Langefeld C.D., Rich S.S., Freedman B.I., Bowden D.W. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes 2004, 53:3007-3012.
27. Yip S.C., Saha S., Chernoff J. PTP1B: a double agent in metabolism and oncogenesis. Trends Biochem. Sci. 2010, 35:442-449.
28. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
29. Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabolotny J.M., Moghal N., Lubkin M., Kim Y.B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., Kahn B.B. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000, 20:5479-5489.
30. Yang Y.M., Seo S.Y., Kim T.H., Kim S.G. Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid. Hepatology 2012, 56:2209-2220.
31. Zinker B.A., Rondinone C.M., Trevillyan J.M., Gum R.J., Clampit J.E., Waring J.F., Xie N., Wilcox D., Jacobson P., Frost L., Kroeger P.E., Reilly R.M., Koterski S., Opgenorth T.J., Ulrich R.G., Crosby S., Butler M., Murray S.F., McKay R.A., Bhanot S., Monia B.P., Jirousek M.R. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11357-11362.
32. Swarbrick M.M., Havel P.J., Levin A.A., Bremer A.A., Stanhope K.L., Butler M., Booten S.L., Graham J.L., McKay R.A., Murray S.F., Watts L.M., Monia B.P., Bhanot S. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology 2009, 150:1670-1679.
33. Florez J.C., Agapakis C.M., Burtt N.P., Sun M., Almgren P., Rastam L., Tuomi T., Gaudet D., Hudson T.J., Daly M.J., Ardlie K.G., Hirschhorn J.N., Groop L., Altshuler D. Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people. Diabetes 2005, 54:1884-1891.
34. Gouni-Berthold I., Giannakidou E., Muller-Wieland D., Faust M., Kotzka J., Berthold H.K., Krone W. The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population. J. Intern. Med. 2005, 257:272-280.
35. Gu P., Jiang W., Du H., Shao J., Lu B., Wang J., Zou D. Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population. J. Endocrinol. Invest. 2010, 33:483-488.
36. Bauer F., Onland-Moret N.C., Niehoff A.G., Elbers C.C., Grobbee D.E., Wijmenga C., van der Schouw Y.T. PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17:28-34.
37. Olivier M., Hsiung C.A., Chuang L.M., Ho L.T., Ting C.T., Bustos V.I., Lee T.M., De Witte A., Chen Y.D., Olshen R., Rodriguez B., Wen C.C., Cox D.R. Single nucleotide polymorphisms in protein tyrosine phosphatase 1beta (PTPN1) are associated with essential hypertension and obesity. Hum. Mol. Genet. 2004, 13:1885-1892.
38. Mosinger B., Tillmann U., Westphal H., Tremblay M.L. Cloning and characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:499-503.
39. Lorenzen J.A., Dadabay C.Y., Fischer E.H. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J. Cell Biol. 1995, 131:631-643.
40. Kleppe M., Lahortiga I., El Chaar T., De Keersmaecker K., Mentens N., Graux C., Van Roosbroeck K., Ferrando A.A., Langerak A.W., Meijerink J.P., Sigaux F., Haferlach T., Wlodarska I., Vandenberghe P., Soulier J., Cools J. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 2010, 42:530-535.
41. Consortium W.T.C.C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
42. Espino-Paisan L., de la Calle H., Fernandez-Arquero M., Figueredo M.A., de la Concha E.G., Urcelay E., Santiago J.L. A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes. Immunogenetics 2011, 63:255-258.
43. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., Brant S.R., Silverberg M.S., Taylor K.D., Barmada M.M., Bitton A., Dassopoulos T., Datta L.W., Green T., Griffiths A.M., Kistner E.O., Murtha M.T., Regueiro M.D., Rotter J.I., Schumm L.P., Steinhart A.H., Targan S.R., Xavier R.J., Libioulle C., Sandor C., Lathrop M., Belaiche J., Dewit O., Gut I., Heath S., Laukens D., Mni M., Rutgeerts P., Van Gossum A., Zelenika D., Franchimont D., Hugot J.P., de Vos M., Vermeire S., Louis E., Cardon L.R., Anderson C.A., Drummond H., Nimmo E., Ahmad T., Prescott N.J., Onnie C.M., Fisher S.A., Marchini J., Ghori J., Bumpstead S., Gwilliam R., Tremelling M., Deloukas P., Mansfield J., Jewell D., Satsangi J., Mathew C.G., Parkes M., Georges M., Daly M.J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 2008, 40:955-962.
44. Umeno J., Asano K., Matsushita T., Matsumoto T., Kiyohara Y., Iida M., Nakamura Y., Kamatani N., Kubo M. Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 2011, 17:2407-2415.
45. Doody K.M., Bourdeau A., Tremblay M.L. T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol. Rev. 2009, 228:325-341.
46. Wiede F., Chew S.H., van Vliet C., Poulton I.J., Kyparissoudis K., Sasmono T., Loh K., Tremblay M.L., Godfrey D.I., Sims N.A., Tiganis T. Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice. PLoS One 2012, 7:e36703.
47. Long S.A., Cerosaletti K., Wan J.Y., Ho J.C., Tatum M., Wei S., Shilling H.G., Buckner J.H. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun. 2011, 12:116-125.
48. Wiede F., Shields B.J., Chew S.H., Kyparissoudis K., van Vliet C., Galic S., Tremblay M.L., Russell S.M., Godfrey D.I., Tiganis T. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 2011, 121:4758-4774.
49. Scharl M., Wojtal K.A., Becker H.M., Fischbeck A., Frei P., Arikkat J., Pesch T., Kellermeier S., Boone D.L., Weber A., Loessner M.J., Vavricka S.R., Fried M., McCole D.F., Rogler G. Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflamm. Bowel Dis. 2012, 18:1287-1302.
50. Braithwaite S.P., Paul S., Nairn A.C., Lombroso P.J. Synaptic plasticity: one STEP at a time. Trends Neurosci. 2006, 29:452-458.
51. Venkitaramani D.V., Moura P.J., Picciotto M.R., Lombroso P.J. Striatal-enriched protein tyrosine phosphatase (STEP) knockout mice have enhanced hippocampal memory. Eur. J. Neurosci. 2011, 33:2288-2298.
52. Venkitaramani D.V., Paul S., Zhang Y., Kurup P., Ding L., Tressler L., Allen M., Sacca R., Picciotto M.R., Lombroso P.J. Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. Synapse 2009, 63:69-81.
53. Goebel-Goody S.M., Baum M., Paspalas C.D., Fernandez S.M., Carty N.C., Kurup P., Lombroso P.J. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol. Rev. 2012, 64:65-87.
54. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4746-4751.
55. Takahashi N., Sakurai T., Davis K.L., Buxbaum J.D. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol. 2011, 93:13-24.
56. Pelov I., Teltsh O., Greenbaum L., Rigbi A., Kanyas-Sarner K., Lerer B., Lombroso P., Kohn Y. Involvement of PTPN5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition. Psychiatr. Genet. 2012, 22:168-176.
57. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28:284-293.
58. Shultz L.D., Rajan T.V., Greiner D.L. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 1997, 15:302-307.
59. Pao L.I., Badour K., Siminovitch K.A., Neel B.G. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu. Rev. Immunol. 2007, 25:473-523.
60. Zhang J., Somani A.K., Siminovitch K.A. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 2000, 12:361-378.
61. Nesterovitch A.B., Gyorfy Z., Hoffman M.D., Moore E.C., Elbuluk N., Tryniszewska B., Rauch T.A., Simon M., Kang S., Fisher G.J., Mikecz K., Tharp M.D., Glant T.T. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am. J. Pathol. 2011, 178:1434-1441.
62. Nesterovitch A.B., Szanto S., Gonda A., Bardos T., Kis-Toth K., Adarichev V.A., Olasz K., Ghassemi-Najad S., Hoffman M.D., Tharp M.D., Mikecz K., Glant T.T. Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans. Am. J. Pathol. 2011, 178:1701-1714.
63. Barr A.J., Knapp S. MAPK-specific tyrosine phosphatases: new targets for drug discovery?. Trends Pharmacol. Sci. 2006, 27:525-530.
64. Gronda M., Arab S., Iafrate B., Suzuki H., Zanke B.W. Hematopoietic protein tyrosine phosphatase suppresses extracellular stimulus-regulated kinase activation. Mol. Cell. Biol. 2001, 21:6851-6858.
65. Kim H.N., Lee E.J., Jung S.C., Lee J.Y., Chung H.W., Kim H.L. Genetic variants that affect length/height in infancy/early childhood in Vietnamese-Korean families. J. Hum. Genet. 2010, 55:681-690.
66. Edouard T., Montagner A., Dance M., Conte F., Yart A., Parfait B., Tauber M., Salles J.P., Raynal P. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?. Cell. Mol. Life Sci. 2007, 64:1585-1590.
67. Grossmann K.S., Rosario M., Birchmeier C., Birchmeier W. The tyrosine phosphatase Shp2 in development and cancer. Adv. Cancer Res. 2010, 106:53-89.
68. Mohi M.G., Neel B.G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 2007, 17:23-30.
69. Tidyman W.E., Rauen K.A. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev. Mol. Med. 2008, 10:e37.
70. Tartaglia M., Martinelli S., Stella L., Bocchinfuso G., Flex E., Cordeddu V., Zampino G., Burgt I., Palleschi A., Petrucci T.C., Sorcini M., Schoch C., Foa R., Emanuel P.D., Gelb B.D. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 2006, 78:279-290.
71. Hof P., Pluskey S., Dhe-Paganon S., Eck M.J., Shoelson S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998, 92:441-450.
72. Hasle H. Malignant diseases in Noonan syndrome and related disorders. Horm. Res. 2009, 72(Suppl. 2):8-14.
73. Jongmans M.C., van der Burgt I., Hoogerbrugge P.M., Noordam K., Yntema H.G., Nillesen W.M., Kuiper R.P., Ligtenberg M.J., van Kessel A.G., van Krieken J.H., Kiemeney L.A., Hoogerbrugge N. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur. J. Hum. Genet. 2011, 19:870-874.
74. Tartaglia M., Gelb B.D. Germ-line and somatic PTPN11 mutations in human disease. Eur. J. Med. Genet. 2005, 48:81-96.
75. Yu Z.H., Xu J., Walls C.D., Chen L., Zhang S., Zhang R., Wu L., Wang L., Liu S., Zhang Z.Y. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J. Biol. Chem. 2013, 288:10472-10482.
76. Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J., Jung A., Hahlen K., Hasle H., Licht J.D., Gelb B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 2003, 34:148-150.
77. Welte T., Zhang S.S., Wang T., Zhang Z., Hesslein D.G., Yin Z., Kano A., Iwamoto Y., Li E., Craft J.E., Bothwell A.L., Fikrig E., Koni P.A., Flavell R.A., Fu X.Y. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1879-1884.
78. Zhang W., Chan R.J., Chen H., Yang Z., He Y., Zhang X., Luo Y., Yin F., Moh A., Miller L.C., Payne R.M., Zhang Z.Y., Fu X.Y., Shou W. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. J. Biol. Chem. 2009, 284:22353-22363.
79. Sobreira N.L., Cirulli E.T., Avramopoulos D., Wohler E., Oswald G.L., Stevens E.L., Ge D., Shianna K.V., Smith J.P., Maia J.M., Gumbs C.E., Pevsner J., Thomas G., Valle D., Hoover-Fong J.E., Goldstein D.B. Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet. 2010, 6:e1000991.
80. Bowen M.E., Boyden E.D., Holm I.A., Campos-Xavier B., Bonafe L., Superti-Furga A., Ikegawa S., Cormier-Daire V., Bovee J.V., Pansuriya T.C., de Sousa S.B., Savarirayan R., Andreucci E., Vikkula M., Garavelli L., Pottinger C., Ogino T., Sakai A., Regazzoni B.M., Wuyts W., Sangiorgi L., Pedrini E., Zhu M., Kozakewich H.P., Kasser J.R., Seidman J.G., Kurek K.C., Warman M.L. Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 2011, 7:e1002050.
81. Goodship J.A., Hall D., Topf A., Mamasoula C., Griffin H., Rahman T.J., Glen E., Tan H., Palomino Doza J., Relton C.L., Bentham J., Bhattacharya S., Cosgrove C., Brook D., Granados-Riveron J., Bu'Lock F.A., O'Sullivan J., Stuart A.G., Parsons J., Cordell H.J., Keavney B. A common variant in the PTPN11 gene contributes to the risk of tetralogy of Fallot. Circ. Cardiovasc. Genet. 2012, 5:287-292.
82. Veillette A., Rhee I., Souza C.M., Davidson D. PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. Immunol. Rev. 2009, 228:312-324.
83. Burridge K., Sastry S.K., Sallee J.L. Regulation of cell adhesion by protein-tyrosine phosphatases. I. Cell-matrix adhesion. J. Biol. Chem. 2006, 281:15593-15596.
84. Harris I.S., Blaser H., Moreno J., Treloar A.E., Gorrini C., Sasaki M., Mason J.M., Knobbe C.B., Rufini A., Halle M., Elia A.J., Wakeham A., Tremblay M.L., Melino G., Done S., Mak T.W. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling. Oncogene 2013, ([Epub ahead of print] PMID: 23435421). 10.1038/onc.2013.24.
85. Sun T., Aceto N., Meerbrey K.L., Kessler J.D., Zhou C., Migliaccio I., Nguyen D.X., Pavlova N.N., Botero M., Huang J., Bernardi R.J., Schmitt E., Hu G., Li M.Z., Dephoure N., Gygi S.P., Rao M., Creighton C.J., Hilsenbeck S.G., Shaw C.A., Muzny D., Gibbs R.A., Wheeler D.A., Osborne C.K., Schiff R., Bentires-Alj M., Elledge S.J., Westbrook T.F. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718.
86. Streit S., Ruhe J.E., Knyazev P., Knyazeva T., Iacobelli S., Peter S., Hoefler H., Ullrich A. PTP-PEST phosphatase variations in human cancer. Cancer Genet. Cytogenet. 2006, 170:48-53.
87. Erdmann K.S. The protein tyrosine phosphatase PTP-Basophil/Basophil-like. Interacting proteins and molecular functions. Eur. J. Biochem. 2003, 270:4789-4798.
88. Nakahira M., Tanaka T., Robson B.E., Mizgerd J.P., Grusby M.J. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 2007, 26:163-176.
89. Wansink D.G., Peters W., Schaafsma I., Sutmuller R.P., Oerlemans F., Adema G.J., Wieringa B., van der Zee C.E., Hendriks W. Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity. Physiol. Genomics 2004, 19:50-60.
90. Abaan O.D., Toretsky J.A. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 2008, 27:205-214.
91. Freiss G., Chalbos D. PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anticancer Agents Med. Chem. 2011, 11:78-88.
92. Yeh S.H., Wu D.C., Tsai C.Y., Kuo T.J., Yu W.C., Chang Y.S., Chen C.L., Chang C.F., Chen D.S., Chen P.J. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin. Cancer Res. 2006, 12:1097-1108.
93. Niu J., Huang Y.J., Wang L.E., Sturgis E.M., Wei Q. Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck. Carcinogenesis 2009, 30:2053-2058.
94. Mita Y., Yasuda Y., Sakai A., Yamamoto H., Toyooka S., Gunduz M., Tanabe S., Naomoto Y., Ouchida M., Shimizu K. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J. Cancer Res. Clin. Oncol. 2010, 136:249-259.
95. Zhu J.H., Chen R., Yi W., Cantin G.T., Fearns C., Yang Y., Yates J.R., Lee J.D. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene 2008, 27:2525-2531.
96. Hoover A.C., Strand G.L., Nowicki P.N., Anderson M.E., Vermeer P.D., Klingelhutz A.J., Bossler A.D., Pottala J.V., Hendriks W.J., Lee J.H. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009, 28:3960-3970.
97. Au A.C., Hernandez P.A., Lieber E., Nadroo A.M., Shen Y.M., Kelley K.A., Gelb B.D., Diaz G.A. Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. Am. J. Hum. Genet. 2010, 87:436-444.
98. Benzinou M., Clermont F.F., Letteboer T.G., Kim J.H., Espejel S., Harradine K.A., Arbelaez J., Luu M.T., Roy R., Quigley D., Higgins M.N., Zaid M., Aouizerat B.E., van Amstel J.K., Giraud S., Dupuis-Girod S., Lesca G., Plauchu H., Hughes C.C., Westermann C.J., Akhurst R.J. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat. Commun. 2012, 3:616.
99. Poernbacher I., Baumgartner R., Marada S.K., Edwards K., Stocker H. Drosophila Pez acts in Hippo signaling to restrict intestinal stem cell proliferation. Curr. Biol. 2012, 22:389-396.
100. Liu X., Yang N., Figel S.A., Wilson K.E., Morrison C.D., Gelman I.H., Zhang J. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 2013, 32(10):1266-1273. (PMID: 22525271).
101. Huang J.M., Nagatomo I., Suzuki E., Mizuno T., Kumagai T., Berezov A., Zhang H., Karlan B., Greene M.I., Wang Q. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 2013, 32(17):2220-2229. (PMID: 22689061).
102. Wang W., Huang J., Wang X., Yuan J., Li X., Feng L., Park J., Chen J. PTPN14 is required for the density-dependent control of YAP1. Genes Dev. 2012, 26(17):1959-1971. (PMID: 22948661).
103. Chen J., Lee G., Fanous A.H., Zhao Z., Jia P., O'Neill A., Walsh D., Kendler K.S., Chen X. Two non-synonymous markers in PTPN21, identified by genome-wide association study data-mining and replication, are associated with schizophrenia. Schizophr. Res. 2011, 131:43-51.
104. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., Ardlie K.G., Huang Q., Smith A.M., Spoerke J.M., Conn M.T., Chang M., Chang S.Y., Saiki R.K., Catanese J.J., Leong D.U., Garcia V.E., McAllister L.B., Jeffery D.A., Lee A.T., Batliwalla F., Remmers E., Criswell L.A., Seldin M.F., Kastner D.L., Amos C.I., Sninsky J.J., Gregersen P.K. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 2004, 75:330-337.
105. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., MacMurray J., Meloni G.F., Lucarelli P., Pellecchia M., Eisenbarth G.S., Comings D., Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 2004, 36:337-338.
106. Burn G.L., Svensson L., Sanchez-Blanco C., Saini M., Cope A.P. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?. FEBS Lett. 2011, 585:3689-3698.
107. Vang T., Miletic A.V., Bottini N., Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007, 40:453-461.
108. Li Y., Liao W., Chang M., Schrodi S.J., Bui N., Catanese J.J., Poon A., Matsunami N., Callis-Duffin K.P., Leppert M.F., Bowcock A.M., Kwok P.Y., Krueger G.G., Begovich A.B. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J. Invest. Dermatol. 2009, 129:629-634.
109. Diaz-Gallo L.M., Espino-Paisan L., Fransen K., Gomez-Garcia M., van Sommeren S., Cardena C., Rodrigo L., Mendoza J.L., Taxonera C., Nieto A., Alcain G., Cueto I., Lopez-Nevot M.A., Bottini N., Barclay M.L., Crusius J.B., van Bodegraven A.A., Wijmenga C., Ponsioen C.Y., Gearry R.B., Roberts R.L., Weersma R.K., Urcelay E., Merriman T.R., Alizadeh B.Z., Martin J. Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 2011, 17:2287-2294.
110. Diaz-Gallo L.M., Gourh P., Broen J., Simeon C., Fonollosa V., Ortego-Centeno N., Agarwal S., Vonk M.C., Coenen M., Riemekasten G., Hunzelmann N., Hesselstrand R., Tan F.K., Reveille J.D., Assassi S., Garcia-Hernandez F.J., Carreira P., Camps M.T., Fernandez-Nebro A., de la Pena P.G., Nearney T., Hilda D., Gonzalez-Gay M.A., Airo P., Beretta L., Scorza R., Herrick A., Worthington J., Pros A., Gomez-Gracia I., Trapiella L., Espinosa G., Castellvi I., Witte T., de Keyser F., Vanthuyne M., Mayes M.D., Radstake T.R., Arnett F.C., Martin J., Rueda B. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann. Rheum. Dis. 2011, 70:454-462.
111. Lamsyah H., Rueda B., Baassi L., Elaouad R., Bottini N., Sadki K., Martin J. Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population. Tissue Antigens 2009, 74:228-232.
112. Hasegawa K., Martin F., Huang G., Tumas D., Diehl L., Chan A.C. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004, 303:685-689.
113. Vang T., Congia M., Macis M.D., Musumeci L., Orru V., Zavattari P., Nika K., Tautz L., Tasken K., Cucca F., Mustelin T., Bottini N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 2005, 37:1317-1319.
114. Zhang J., Zahir N., Jiang Q., Miliotis H., Heyraud S., Meng X., Dong B., Xie G., Qiu F., Hao Z., McCulloch C.A., Keystone E.C., Peterson A.C., Siminovitch K.A. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 2011, 43:902-907.
115. Guillem V., Amat P., Cervantes F., Alvarez-Larran A., Cervera J., Maffioli M., Bellosillo B., Collado M., Marugan I., Martinez-Ruiz F., Hernandez-Boluda J.C. Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leuk. Res. 2012, 36:174-181.
116. Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J., Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J., Clark J.M. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J. Biol. Chem. 2006, 281:11002-11010.
117. Yu X., Chen M., Zhang S., Yu Z.H., Sun J.P., Wang L., Liu S., Imasaki T., Takagi Y., Zhang Z.Y. Substrate specificity of lymphoid-specific tyrosine phosphatase (Lyp) and identification of Src kinase-associated protein of 55kDa homolog (SKAP-HOM) as a Lyp substrate. J. Biol. Chem. 2011, 286:30526-30534.
118. Maine C.J., Hamilton-Williams E.E., Cheung J., Stanford S.M., Bottini N., Wicker L.S., Sherman L.A. PTPN22 alters the development of regulatory T cells in the thymus. J. Immunol. 2012, 188:5267-5275.
119. Bodrikov V., Sytnyk V., Leshchyns'ka I., den Hertog J., Schachner M. NCAM induces CaMKIIalpha-mediated RPTPalpha phosphorylation to enhance its catalytic activity and neurite outgrowth. J. Cell Biol. 2008, 182:1185-1200.
120. Ye H., Tan Y.L., Ponniah S., Takeda Y., Wang S.Q., Schachner M., Watanabe K., Pallen C.J., Xiao Z.C. Neural recognition molecules CHL1 and NB-3 regulate apical dendrite orientation in the neocortex via PTP alpha. EMBO J. 2008, 27:188-200.
121. Ye H., Zhao T., Tan Y.L., Liu J., Pallen C.J., Xiao Z.C. Receptor-like protein-tyrosine phosphatase alpha enhances cell surface expression of neural adhesion molecule NB-3. J. Biol. Chem. 2011, 286:26071-26080.
122. Zeng L., D'Alessandri L., Kalousek M.B., Vaughan L., Pallen C.J. Protein tyrosine phosphatase alpha (PTPalpha) and contactin form a novel neuronal receptor complex linked to the intracellular tyrosine kinase fyn. J. Cell Biol. 1999, 147:707-714.
123. Su J., Muranjan M., Sap J. Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr. Biol. 1999, 9:505-511.
124. Vacaresse N., Moller B., Danielsen E.M., Okada M., Sap J. Activation of c-Src and Fyn kinases by protein-tyrosine phosphatase RPTPalpha is substrate-specific and compatible with lipid raft localization. J. Biol. Chem. 2008, 283:35815-35824.
125. Takahashi N., Nielsen K.S., Aleksic B., Petersen S., Ikeda M., Kushima I., Vacaresse N., Ujike H., Iwata N., Dubreuil V., Mirza N., Sakurai T., Ozaki N., Buxbaum J.D., Sap J. Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase alpha to schizophrenia. Biol. Psychiatry 2011, 70:626-635.
126. Shi J., Potash J.B., Knowles J.A., Weissman M.M., Coryell W., Scheftner W.A., Lawson W.B., DePaulo J.R., Gejman P.V., Sanders A.R., Johnson J.K., Adams P., Chaudhury S., Jancic D., Evgrafov O., Zvinyatskovskiy A., Ertman N., Gladis M., Neimanas K., Goodell M., Hale N., Ney N., Verma R., Mirel D., Holmans P., Levinson D.F. Genome-wide association study of recurrent early-onset major depressive disorder. Mol. Psychiatry 2011, 16:193-201.
127. Sperber B.R., Boyle-Walsh E.A., Engleka M.J., Gadue P., Peterson A.C., Stein P.L., Scherer S.S., McMorris F.A. A unique role for Fyn in CNS myelination. J. Neurosci. 2001, 21:2039-2047.
128. Hossain S., Fragoso G., Mushynski W.E., Almazan G. Regulation of peripheral myelination by Src-like kinases. Exp. Neurol. 2010, 226:47-57.
129. Trowbridge I.S. CD45. A prototype for transmembrane protein tyrosine phosphatases. J. Biol. Chem. 1991, 266:23517-23520.
130. Fischer E.H., Charbonneau H., Tonks N.K. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science 1991, 253:401-406.
131. Alexander D.R. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin. Immunol. 2000, 12:349-359.
132. Hermiston M.L., Xu Z., Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu. Rev. Immunol. 2003, 21:107-137.
133. Panchal R.G., Bradfute S.B., Peyser B.D., Warfield K.L., Ruthel G., Lane D., Kenny T.A., Anderson A.O., Raschke W.C., Bavari S. Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection. Cell Host Microbe 2009, 6:162-173.
134. Kung C., Pingel J.T., Heikinheimo M., Klemola T., Varkila K., Yoo L.I., Vuopala K., Poyhonen M., Uhari M., Rogers M., Speck S.H., Chatila T., Thomas M.L. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat. Med. 2000, 6:343-345.
135. Tchilian E.Z., Wallace D.L., Wells R.S., Flower D.R., Morgan G., Beverley P.C. A deletion in the gene encoding the CD45 antigen in a patient with SCID. J. Immunol. 2001, 166:1308-1313.
136. Roberts J.L., Buckley R.H., Luo B., Pei J., Lapidus A., Peri S., Wei Q., Shin J., Parrott R.E., Dunbrack R.L., Testa J.R., Zhong X.P., Wiest D.L. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10456-10461.
137. Nakahara J., Seiwa C., Tan-Takeuchi K., Gotoh M., Kishihara K., Ogawa M., Asou H., Aiso S. Involvement of CD45 in central nervous system myelination. Neurosci. Lett. 2005, 379:116-121.
138. Jacobsen M., Schweer D., Ziegler A., Gaber R., Schock S., Schwinzer R., Wonigeit K., Lindert R.B., Kantarci O., Schaefer-Klein J., Schipper H.I., Oertel W.H., Heidenreich F., Weinshenker B.G., Sommer N., Hemmer B. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat. Genet. 2000, 26:495-499.
139. Thude H., Hundrieser J., Wonigeit K., Schwinzer R. A point mutation in the human CD45 gene associated with defective splicing of exon A. Eur. J. Immunol. 1995, 25:2101-2106.
140. Szvetko A.L., Jones A., Mackenzie J., Tajouri L., Csurhes P.A., Greer J.M., Pender M.P., Griffiths L.R. An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. Brain Res. 2009, 1255:148-152.
141. Dawes R., Hennig B., Irving W., Petrova S., Boxall S., Ward V., Wallace D., Macallan D.C., Thursz M., Hill A., Bodmer W., Beverley P.C., Tchilian E.Z. Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. J. Med. Genet. 2006, 43:678-684.
142. Raychaudhuri S., Thomson B.P., Remmers E.F., Eyre S., Hinks A., Guiducci C., Catanese J.J., Xie G., Stahl E.A., Chen R., Alfredsson L., Amos C.I., Ardlie K.G., Consortium B., Barton A., Bowes J., Burtt N.P., Chang M., Coblyn J., Costenbader K.H., Criswell L.A., Crusius J.B., Cui J., De Jager P.L., Ding B., Emery P., Flynn E., Harrison P., Hocking L.J., Huizinga T.W., Kastner D.L., Ke X., Kurreeman F.A., Lee A.T., Liu X., Li Y., Martin P., Morgan A.W., Padyukov L., Reid D.M., Seielstad M., Seldin M.F., Shadick N.A., Steer S., Tak P.P., Thomson W., Van der Helm-van Mil A.H., van der Horst-Bruinsma I.E., Weinblatt M.E., Wilson A.G., Wolbink G.J., Wordsworth P., Consortium Y., Altshuler D., Karlson E.W., Toes R.E., de Vries N., Begovich A.B., Siminovitch K.A., Worthington J., Klareskog L., Gregersen P.K., Daly M.J., Plenge R.M. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat. Genet. 2009, 41:1313-1318.
143. Plant D., Prajapati R., Hyrich K.L., Morgan A.W., Wilson A.G., Isaacs J.D., Barton A. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012, 64:665-670. G. Biologics in Rheumatoid Arthritis, S. Genomics StudyS. Genomics Study.
144. Cui J., Saevarsdottir S., Thomson B., Padyukov L., Van der Helm-van Mil A.H., Nititham J., Hughes L.B., de Vries N., Raychaudhuri S., Alfredsson L., Askling J., Wedren S., Ding B., Guiducci C., Wolbink G.J., Crusius J.B., van der Horst-Bruinsma I.E., Herenius M., Weinblatt M.E., Shadick N.A., Worthington J., Batliwalla F., Kern M., Morgan A.W., Wilson A.G., Isaacs J.D., Hyrich K., Seldin M.F., Moreland L.W., Behrens T.W., Allaart C.F., Criswell L.A., Huizinga T.W., Tak P.P., Bridges S.L., Toes R.E., Barton A., Klareskog L., Gregersen P.K., Karlson E.W., Plenge R.M. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010, 62:1849-1861.
145. Trenkwalder C., Hogl B., Winkelmann J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J. Neurol. 2009, 256:539-553.
146. Lohmann-Hedrich K., Neumann A., Kleensang A., Lohnau T., Muhle H., Djarmati A., Konig I.R., Pramstaller P.P., Schwinger E., Kramer P.L., Ziegler A., Stephani U., Klein C. Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci?. Neurology 2008, 70:686-694.
147. Schormair B., Kemlink D., Roeske D., Eckstein G., Xiong L., Lichtner P., Ripke S., Trenkwalder C., Zimprich A., Stiasny-Kolster K., Oertel W., Bachmann C.G., Paulus W., Hogl B., Frauscher B., Gschliesser V., Poewe W., Peglau I., Vodicka P., Vavrova J., Sonka K., Nevsimalova S., Montplaisir J., Turecki G., Rouleau G., Gieger C., Illig T., Wichmann H.E., Holsboer F., Muller-Myhsok B., Meitinger T., Winkelmann J. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat. Genet. 2008, 40:946-948.
148. Yang Q., Li L., Yang R., Shen G.Q., Chen Q., Foldvary-Schaefer N., Ondo W.G., Wang Q.K. Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome. Mov. Disord. 2011, 26:516-519.
149. Uetani N., Chagnon M.J., Kennedy T.E., Iwakura Y., Tremblay M.L. Mammalian motoneuron axon targeting requires receptor protein tyrosine phosphatases sigma and delta. J. Neurosci. 2006, 26:5872-5880.
150. Valnegri P., Montrasio C., Brambilla D., Ko J., Passafaro M., Sala C. The X-linked intellectual disability protein IL1RAPL1 regulates excitatory synapse formation by binding PTPdelta and RhoGAP2. Hum. Mol. Genet. 2011, 20:4797-4809.
151. Du Y., Su T., Tan X., Li X., Xie J., Wang G., Shen J., Hou J., Cao G. Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma. Gene 2013, 512:64-69.
152. Shyur S.D., Wang J.Y., Lin C.G., Hsiao Y.H., Liou Y.H., Wu Y.J., Wu L.S. The polymorphisms of protein-tyrosine phosphatase receptor-type delta gene and its association with pediatric asthma in the Taiwanese population. Eur. J. Hum. Genet. 2008, 16:1283-1288.
153. Li X., Tan X., Yu Y., Chen H., Chang W., Hou J., Xu D., Ma L., Cao G. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer 2011, 117:4201-4211.
154. Meehan M., Parthasarathi L., Moran N., Jefferies C.A., Foley N., Lazzari E., Murphy D., Ryan J., Ortiz B., Fabius A.W., Chan T.A., Stallings R.L. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol. Cancer 2012, 11:6.
155. Schaapveld R.Q., Schepens J.T., Robinson G.W., Attema J., Oerlemans F.T., Fransen J.A., Streuli M., Wieringa B., Hennighausen L., Hendriks W.J. Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity. Dev. Biol. 1997, 188:134-146.
156. Van Lieshout E.M., Van der Heijden I., Hendriks W.J., Van der Zee C.E. A decrease in size and number of basal forebrain cholinergic neurons is paralleled by diminished hippocampal cholinergic innervation in mice lacking leukocyte common antigen-related protein tyrosine phosphatase activity. Neuroscience 2001, 102:833-841.
157. Dunah A.W., Hueske E., Wyszynski M., Hoogenraad C.C., Jaworski J., Pak D.T., Simonetta A., Liu G., Sheng M. LAR receptor protein tyrosine phosphatases in the development and maintenance of excitatory synapses. Nat. Neurosci. 2005, 8:458-467.
158. Bernabeu R., Yang T., Xie Y., Mehta B., Ma S.Y., Longo F.M. Downregulation of the LAR protein tyrosine phosphatase receptor is associated with increased dentate gyrus neurogenesis and an increased number of granule cell layer neurons. Mol. Cell. Neurosci. 2006, 31:723-738.
159. Niu X.L., Li J., Hakim Z.S., Rojas M., Runge M.S., Madamanchi N.R. Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J. Biol. Chem. 2007, 282:19808-19819.
160. Ausavarat S., Tongkobpetch S., Praphanphoj V., Mahatumarat C., Rojvachiranonda N., Snabboon T., Markello T.C., Gahl W.A., Suphapeetiporn K., Shotelersuk V. PTPRF is disrupted in a patient with syndromic amastia. BMC Med. Genet. 2011, 12:46.
161. Walchli S., Curchod M.L., Gobert R.P., Arkinstall S., Hooft van Huijsduijnen R. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on "substrate-trapping" mutants. J. Biol. Chem. 2000, 275:9792-9796.
162. Li P.M., Zhang W.R., Goldstein B.J. Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. Cell. Signal. 1996, 8:467-473.
163. Zhang W.R., Li P.M., Oswald M.A., Goldstein B.J. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol. Endocrinol. 1996, 10:575-584.
164. Mander A., Hodgkinson C.P., Sale G.J. Knock-down of LAR protein tyrosine phosphatase induces insulin resistance. FEBS Lett. 2005, 579:3024-3028.
165. Norris K., Norris F., Kono D.H., Vestergaard H., Pedersen O., Theofilopoulos A.N., Moller N.P. Expression of protein-tyrosine phosphatases in the major insulin target tissues. FEBS Lett. 1997, 415:243-248.
166. Zabolotny J.M., Kim Y.B., Peroni O.D., Kim J.K., Pani M.A., Boss O., Klaman L.D., Kamatkar S., Shulman G.I., Kahn B.B., Neel B.G. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5187-5192.
167. Miscio G., Tassi V., Coco A., Soccio T., Di Paola R., Prudente S., Baratta R., Frittitta L., Ludovico O., Padovano L., Dallapiccola B., Di Mario U., De Cosmo S., Trischitta V. The allelic variant of LAR gene promoter -127 bp T->A is associated with reduced risk of obesity and other features related to insulin resistance. J. Mol. Med. 2004, 82:459-466.
168. Menzaghi C., Paroni G., De Bonis C., Coco A., Vigna C., Miscio G., Lanna P., Tassi V., Bacci S., Trischitta V. The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes. J. Intern. Med. 2008, 263:653-654.
169. Ruivenkamp C.A., van Wezel T., Zanon C., Stassen A.P., Vlcek C., Csikos T., Klous A.M., Tripodis N., Perrakis A., Boerrigter L., Groot P.C., Lindeman J., Mooi W.J., Meijjer G.A., Scholten G., Dauwerse H., Paces V., van Zandwijk N., van Ommen G.J., Demant P. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet. 2002, 31:295-300.
170. Takahashi T., Takahashi K., St John P.L., Fleming P.A., Tomemori T., Watanabe T., Abrahamson D.R., Drake C.J., Shirasawa T., Daniel T.O. A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol. Cell. Biol. 2003, 23:1817-1831.
171. Takahashi T., Takahashi K., Mernaugh R.L., Tsuboi N., Liu H., Daniel T.O. A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. Blood 2006, 108:1234-1242.
172. Trapasso F., Drusco A., Costinean S., Alder H., Aqeilan R.I., Iuliano R., Gaudio E., Raso C., Zanesi N., Croce C.M., Fusco A. Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol. 2006, 25:376-382.
173. Venkatachalam R., Ligtenberg M.J., Hoogerbrugge N., Schackert H.K., Gorgens H., Hahn M.M., Kamping E.J., Vreede L., Hoenselaar E., van der Looij E., Goossens M., Churchman M., Carvajal-Carmona L., Tomlinson I.P., de Bruijn D.R., Van Kessel A.G., Kuiper R.P. Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early-onset familial colorectal cancer. Gastroenterology 2010, 139:2221-2224.
174. Ligtenberg M.J., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., Voorendt M., Lee T.Y., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J., Tsui W.Y., Kong C.K., Brunner H.G., van Kessel A.G., Yuen S.T., van Krieken J.H., Leung S.Y., Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 2009, 41:112-117.
175. Berger A.H., Knudson A.G., Pandolfi P.P. A continuum model for tumour suppression. Nature 2011, 476:163-169.
176. Lesueur F., Pharoah P.D., Laing S., Ahmed S., Jordan C., Smith P.L., Luben R., Wareham N.J., Easton D.F., Dunning A.M., Ponder B.A. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum. Mol. Genet. 2005, 14:2349-2356.
177. Iuliano R., Palmieri D., He H., Iervolino A., Borbone E., Pallante P., Cianflone A., Nagy R., Alder H., Calin G.A., Trapasso F., Giordano C., Croce C.M., de la Chapelle A., Fusco A. Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr. Relat. Cancer 2010, 17:1001-1006.
178. Sallee J.L., Burridge K. Density-enhanced phosphatase 1 regulates phosphorylation of tight junction proteins and enhances barrier function of epithelial cells. J. Biol. Chem. 2009, 284:14997-15006.
179. Rollin J., Pouplard C., Gratacap M.P., Leroux D., May M.A., Aupart M., Gouilleux-Gruart V., Payrastre B., Gruel Y. Polymorphisms of protein tyrosine phosphatase CD148 influence FcgammaRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012, 120:1309-1316.
180. Hermiston M.L., Zikherman J., Zhu J.W. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol. Rev. 2009, 228:288-311.
181. Senis Y.A., Tomlinson M.G., Ellison S., Mazharian A., Lim J., Zhao Y., Kornerup K.N., Auger J.M., Thomas S.G., Dhanjal T., Kalia N., Zhu J.W., Weiss A., Watson S.P. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood 2009, 113:4942-4954.
182. Katsumoto T.R., Kudo M., Chen C., Sundaram A., Callahan E.C., Zhu J.W., Lin J., Rosen C.E., Manz B.N., Lee J.W., Matthay M.A., Huang X., Sheppard D., Weiss A. The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases. J. Clin. Invest. 2013, 123:2037-2048.
183. Zhu J.W., Doan K., Park J., Chau A.H., Zhang H., Lowell C.A., Weiss A. Receptor-like tyrosine phosphatases CD45 and CD148 have distinct functions in chemoattractant-mediated neutrophil migration and response to S. aureus. Immunity 2011, 35:757-769.
184. Cai T., Hirai H., Zhang G., Zhang M., Takahashi N., Kasai H., Satin L.S., Leapman R.D., Notkins A.L. Deletion of Ia-2 and/or Ia-2beta in mice decreases insulin secretion by reducing the number of dense core vesicles. Diabetologia 2011, 54:2347-2357.
185. Drake P.G., Peters G.H., Andersen H.S., Hendriks W., Moller N.P. A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2beta). Biochem. J. 2003, 373:393-401.
186. Caromile L.A., Oganesian A., Coats S.A., Seifert R.A., Bowen-Pope D.F. The neurosecretory vesicle protein phogrin functions as a phosphatidylinositol phosphatase to regulate insulin secretion. J. Biol. Chem. 2010, 285:10487-10496.
187. Lionel A.C., Crosbie J., Barbosa N., Goodale T., Thiruvahindrapuram B., Rickaby J., Gazzellone M., Carson A.R., Howe J.L., Wang Z., Wei J., Stewart A.F., Roberts R., McPherson R., Fiebig A., Franke A., Schreiber S., Zwaigenbaum L., Fernandez B.A., Roberts W., Arnold P.D., Szatmari P., Marshall C.R., Schachar R., Scherer S.W. Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci. Transl. Med. 2011, 3:95ra75.
188. Yang B.Z., Han S., Kranzler H.R., Farrer L.A., Gelernter J. A genomewide linkage scan of cocaine dependence and major depressive episode in two populations. Neuropsychopharmacology 2011, 36:2422-2430.
189. Wiggins R.C., Wiggins J.E., Goyal M., Wharram B.L., Thomas P.E. Molecular cloning of cDNAs encoding human GLEPP1, a membrane protein tyrosine phosphatase: characterization of the GLEPP1 protein distribution in human kidney and assignment of the GLEPP1 gene to human chromosome 12p12-p13. Genomics 1995, 27:174-181.
190. Wharram B.L., Goyal M., Gillespie P.J., Wiggins J.E., Kershaw D.B., Holzman L.B., Dysko R.C., Saunders T.L., Samuelson L.C., Wiggins R.C. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J. Clin. Invest. 2000, 106:1281-1290.
191. Ozaltin F., Ibsirlioglu T., Taskiran E.Z., Baydar D.E., Kaymaz F., Buyukcelik M., Kilic B.D., Balat A., Iatropoulos P., Asan E., Akarsu N.A., Schaefer F., Yilmaz E., Bakkaloglu A. Disruption of PTPRO causes childhood-onset nephrotic syndrome. Am. J. Hum. Genet. 2011, 89:139-147.
192. Vats A.N. Genetics of idiopathic nephrotic syndrome. Indian J. Pediatr. 2005, 72:777-783.
193. Yu M., Lin G., Arshadi N., Kalatskaya I., Xue B., Haider S., Nguyen F., Boutros P.C., Elson A., Muthuswamy L.B., Tonks N.K., Muthuswamy S.K. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol. Cell. Biol. 2012, 32:3913-3924.
194. Hower A.E., Beltran P.J., Bixby J.L. Dimerization of tyrosine phosphatase PTPRO decreases its activity and ability to inactivate TrkC. J. Neurochem. 2009, 110:1635-1647.
195. LeBlanc M., Kulle B., Sundet K., Agartz I., Melle I., Djurovic S., Frigessi A., Andreassen O.A. Genome-wide study identifies PTPRO and WDR72 and FOXQ1-SUMO1P1 interaction associated with neurocognitive function. J. Psychiatr. Res. 2012, 46:271-278.
196. Gonzalez-Brito M.R., Bixby J.L. Protein tyrosine phosphatase receptor type O regulates development and function of the sensory nervous system. Mol. Cell. Neurosci. 2009, 42:458-465.
197. Chen B., Bixby J.L. A novel substrate of receptor tyrosine phosphatase PTPRO is required for nerve growth factor-induced process outgrowth. J. Neurosci. 2005, 25:880-888.
198. Oganesian A., Poot M., Daum G., Coats S.A., Wright M.B., Seifert R.A., Bowen-Pope D.F. Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival and proliferation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7563-7568.
199. Schraders M., Oostrik J., Huygen P.L., Strom T.M., van Wijk E., Kunst H.P., Hoefsloot L.H., Cremers C.W., Admiraal R.J., Kremer H. Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction. Am. J. Hum. Genet. 2010, 86:604-610.
200. Shahin H., Rahil M., Abu Rayan A., Avraham K.B., King M.C., Kanaan M., Walsh T. Nonsense mutation of the stereociliar membrane protein gene PTPRQ in human hearing loss DFNB84. J. Med. Genet. 2010, 47:643-645.
201. Goodyear R.J., Legan P.K., Wright M.B., Marcotti W., Oganesian A., Coats S.A., Booth C.J., Kros C.J., Seifert R.A., Bowen-Pope D.F., Richardson G.P. A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles. J. Neurosci. 2003, 23:9208-9219.
202. Goodyear R.J., Jones S.M., Sharifi L., Forge A., Richardson G.P. Hair bundle defects and loss of function in the vestibular end organs of mice lacking the receptor-like inositol lipid phosphatase PTPRQ. J. Neurosci. 2012, 32:2762-2772.
203. Hendriks W.J., Dilaver G., Noordman Y.E., Kremer B., Fransen J.A. PTPRR protein tyrosine phosphatase isoforms and locomotion of vesicles and mice. Cerebellum 2009, 8:80-88.
204. Chirivi R.G., Noordman Y.E., Van der Zee C.E., Hendriks W.J. Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice. J. Neurochem. 2007, 101:829-840.
205. Pulido R., Zúñiga A., Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 1998, 17:7337-7350.
206. Zúñiga A., Torres J., Ubeda J., Pulido R. Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm. J. Biol. Chem. 1999, 274:21900-21907.
207. Muñoz J.J., Tárrega C., Blanco-Aparicio C., Pulido R. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochem. J. 2003, 372:193-201.
208. Buschbeck M., Eickhoff J., Sommer M.N., Ullrich A. Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway. J. Biol. Chem. 2002, 277:29503-29509.
209. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., Manji H.K., Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 2003, 23:7311-7316.
210. Chen G., Manji H.K. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr. Opin. Psychiatry 2006, 19:313-323.
211. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., Newton S.S., Duman R.S. A negative regulator of MAP kinase causes depressive behavior. Nat. Med. 2010, 16:1328-1332.
212. Elchebly M., Wagner J., Kennedy T.E., Lanctot C., Michaliszyn E., Itie A., Drouin J., Tremblay M.L. Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat. Genet. 1999, 21:330-333.
213. Muise A.M., Walters T., Wine E., Griffiths A.M., Turner D., Duerr R.H., Regueiro M.D., Ngan B.Y., Xu W., Sherman P.M., Silverberg M.S., Rotin D. Protein-tyrosine phosphatase sigma is associated with ulcerative colitis. Curr. Biol. 2007, 17:1212-1218.
214. Chagnon M.J., Wu C.L., Nakazawa T., Yamamoto T., Noda M., Blanchetot C., Tremblay M.L. Receptor tyrosine phosphatase sigma (RPTPsigma) regulates, p250GAP, a novel substrate that attenuates Rac signaling. Cell. Signal. 2010, 22:1626-1633.
215. Thompson K.M., Uetani N., Manitt C., Elchebly M., Tremblay M.L., Kennedy T.E. Receptor protein tyrosine phosphatase sigma inhibits axonal regeneration and the rate of axon extension. Mol. Cell. Neurosci. 2003, 23:681-692.
216. Sapieha P.S., Duplan L., Uetani N., Joly S., Tremblay M.L., Kennedy T.E., Di Polo A. Receptor protein tyrosine phosphatase sigma inhibits axon regrowth in the adult injured CNS. Mol. Cell. Neurosci. 2005, 28:625-635.
217. Uetani N., Bertozzi K., Chagnon M.J., Hendriks W., Tremblay M.L., Bouchard M. Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases. J. Clin. Invest. 2009, 119:924-935.
218. Morris L.G., Taylor B.S., Bivona T.G., Gong Y., Eng S., Brennan C.W., Kaufman A., Kastenhuber E.R., Banuchi V.E., Singh B., Heguy A., Viale A., Mellinghoff I.K., Huse J., Ganly I., Chan T.A. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19024-19029.
219. Suarez Pestana E., Tenev T., Gross S., Stoyanov B., Ogata M., Bohmer F.D. The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells. Oncogene 1999, 18:4069-4079.
220. Chagnon M.J., Elchebly M., Uetani N., Dombrowski L., Cheng A., Mooney R.A., Marette A., Tremblay M.L. Altered glucose homeostasis in mice lacking the receptor protein tyrosine phosphatase sigma. Can. J. Physiol. Pharmacol. 2006, 84:755-763.
221. Langberg E.C., Gu H.F., Nordman S., Efendic S., Ostenson C.G. Genetic variation in receptor protein tyrosine phosphatase sigma is associated with type 2 diabetes in Swedish Caucasians. Eur. J. Endocrinol. 2007, 157:459-464.
222. Lamprianou S., Harroch S. Receptor protein tyrosine phosphatase from stem cells to mature glial cells of the central nervous system. J. Mol. Neurosci. 2006, 29:241-255.
223. Harroch S., Palmeri M., Rosenbluth J., Custer A., Okigaki M., Shrager P., Blum M., Buxbaum J.D., Schlessinger J. No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta. Mol. Cell. Biol. 2000, 20:7706-7715.
224. Cohen S., Shoshana O.Y., Zelman-Toister E., Maharshak N., Binsky-Ehrenreich I., Gordin M., Hazan-Halevy I., Herishanu Y., Shvidel L., Haran M., Leng L., Bucala R., Harroch S., Shachar I. The cytokine midkine and its receptor RPTPzeta regulate B cell survival in a pathway induced by CD74. J. Immunol. 2012, 188:259-269.
225. Niisato K., Fujikawa A., Komai S., Shintani T., Watanabe E., Sakaguchi G., Katsuura G., Manabe T., Noda M. Age-dependent enhancement of hippocampal long-term potentiation and impairment of spatial learning through the Rho-associated kinase pathway in protein tyrosine phosphatase receptor type Z-deficient mice. J. Neurosci. 2005, 25:1081-1088.
226. Harroch S., Furtado G.C., Brueck W., Rosenbluth J., Lafaille J., Chao M., Buxbaum J.D., Schlessinger J. A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nat. Genet. 2002, 32:411-414.
227. Kuboyama K., Fujikawa A., Masumura M., Suzuki R., Matsumoto M., Noda M. Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination. PLoS One 2012, 7:e48797.
228. Huang J.K., Ferrari C.C., Monteiro de Castro G., Lafont D., Zhao C., Zaratin P., Pouly S., Greco B., Franklin R.J. Accelerated axonal loss following acute CNS demyelination in mice lacking protein tyrosine phosphatase receptor type z. Am. J. Pathol. 2012, 181:1518-1523.
229. Fujikawa A., Shirasaka D., Yamamoto S., Ota H., Yahiro K., Fukada M., Shintani T., Wada A., Aoyama N., Hirayama T., Fukamachi H., Noda M. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat. Genet. 2003, 33:375-381.
230. Buxbaum J.D., Georgieva L., Young J.J., Plescia C., Kajiwara Y., Jiang Y., Moskvina V., Norton N., Peirce T., Williams H., Craddock N.J., Carroll L., Corfas G., Davis K.L., Owen M.J., Harroch S., Sakurai T., O'Donovan M.C. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Mol. Psychiatry 2008, 13:162-172.
231. Buxbaum J.D., Young J., Georgieva L., Plescia C., Harroch S., Moskvina V., Owen M., Sakurai T., O'Donovan M. Identification of PTPRZ1 as a schizophrenia susceptibility gene. Schizophr. Bull. 2007, 33:295-295.
232. Takahashi N., Sakurai T., Bozdagi-Gunal O., Dorr N., Moy J., Krug L., Gama-sosa M., Elder G., Koch R., Walker R., Hof P., Davis K., Buxbaum J.D. Increased expression of receptor phosphotyrosine phosphatase-z is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes. Transl. Psychiatry 2011, 1:e8.
233. Ito Y., Yamada S., Takahashi N., Saito S., Yoshimi A., Inada T., Noda Y., Ozaki N. No association between the protein tyrosine phosphatase, receptor-type, Z Polypeptide 1 (PTPRZ1) gene and schizophrenia in the Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1013-1018.
234. Berretta S., Misra R., Pantazopoulos H. Rptpz/Phosphacan abnormalities in the amygdala of subjects diagnosed with schizophrenia. Schizophr. Bull. 2011, 37:187-187.
235. Fujikawa A., Fukada M., Makioka Y., Suzuki R., Chow J.P., Matsumoto M., Noda M. Consensus substrate sequence for protein-tyrosine phosphatase receptor type Z. J. Biol. Chem. 2011, 286:37137-37146.
236. Xu Y., Fisher G.J. Receptor type protein tyrosine phosphatases (RPTPs)-roles in signal transduction and human disease. J. Cell Commun. Signal. 2012, 6:125-138.
237. Owens D.M., Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007, 26:3203-3213.
238. Kondoh K., Nishida E. Regulation of MAP kinases by MAP kinase phosphatases. Biochim. Biophys. Acta 2007, 1773:1227-1237.
239. Wancket L.M., Frazier W.J., Liu Y. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci. 2012, 90:237-248.
240. Salojin K., Oravecz T. Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes. J. Leukoc. Biol. 2007, 81:860-869.
241. Jin Y., Hu D., Peterson E.L., Eng C., Levin A.M., Wells K., Beckman K., Kumar R., Seibold M.A., Karungi G., Zoratti A., Gaggin J., Campbell J., Galanter J., Chapela R., Rodriguez-Santana J.R., Watson H.G., Meade K., Lenoir M., Rodriguez-Cintron W., Avila P.C., Lanfear D.E., Burchard E.G., Williams L.K. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J. Allergy Clin. Immunol. 2010, 126:618-625. (e611-612).
242. Quante T., Ng Y.C., Ramsay E.E., Henness S., Allen J.C., Parmentier J., Ge Q., Ammit A.J. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am. J. Respir. Cell Mol. Biol. 2008, 39:208-217.
243. Manetsch M., Che W., Seidel P., Chen Y., Ammit A.J. MKP-1: a negative feedback effector that represses MAPK-mediated pro-inflammatory signaling pathways and cytokine secretion in human airway smooth muscle cells. Cell. Signal. 2012, 24:907-913.
244. Moutzouris J.P., Che W., Ramsay E.E., Manetsch M., Alkhouri H., Bjorkman A.M., Schuster F., Ge Q., Ammit A.J. Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion. Biochim. Biophys. Acta 2010, 1803:416-423.
245. Caunt C.J., Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 2013, 280(2):489-504. (PMID: 22812510).
246. Li C., Scott D.A., Hatch E., Tian X., Mansour S.L. Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development 2007, 134:167-176.
247. Maillet M., Purcell N.H., Sargent M.A., York A.J., Bueno O.F., Molkentin J.D. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J. Biol. Chem. 2008, 283:31246-31255.
248. Lee K.Y., Ahn Y.M., Joo E.J., Chang J.S., Kim Y.S. The association of DUSP6 gene with schizophrenia and bipolar disorder: its possible role in the development of bipolar disorder. Mol. Psychiatry 2006, 11:425-426.
249. Kim S.H., Shin S.Y., Lee K.Y., Joo E.J., Song J.Y., Ahn Y.M., Lee Y.H., Kim Y.S. The genetic association of DUSP6 with bipolar disorder and its effect on ERK activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 37(1):41-49. (PMID: 22155192).
250. Kalkman H.O. Potential opposite roles of the extracellular signal-regulated kinase (ERK) pathway in autism spectrum and bipolar disorders. Neurosci. Biobehav. Rev. 2012, 36:2206-2213.
251. Voight B.F., Scott L.J., Steinthorsdottir V., Morris A.P., Dina C., Welch R.P., Zeggini E., Huth C., Aulchenko Y.S., Thorleifsson G., McCulloch L.J., Ferreira T., Grallert H., Amin N., Wu G., Willer C.J., Raychaudhuri S., McCarroll S.A., Langenberg C., Hofmann O.M., Dupuis J., Qi L., Segre A.V., van Hoek M., Navarro P., Ardlie K., Balkau B., Benediktsson R., Bennett A.J., Blagieva R., Boerwinkle E., Bonnycastle L.L., Bengtsson Bostrom K., Bravenboer B., Bumpstead S., Burtt N.P., Charpentier G., Chines P.S., Cornelis M., Couper D.J., Crawford G., Doney A.S., Elliott K.S., Elliott A.L., Erdos M.R., Fox C.S., Franklin C.S., Ganser M., Gieger C., Grarup N., Green T., Griffin S., Groves C.J., Guiducci C., Hadjadj S., Hassanali N., Herder C., Isomaa B., Jackson A.U., Johnson P.R., Jorgensen T., Kao W.H., Klopp N., Kong A., Kraft P., Kuusisto J., Lauritzen T., Li M., Lieverse A., Lindgren C.M., Lyssenko V., Marre M., Meitinger T., Midthjell K., Morken M.A., Narisu N., Nilsson P., Owen K.R., Payne F., Perry J.R., Petersen A.K., Platou C., Proenca C., Prokopenko I., Rathmann W., Rayner N.W., Robertson N.R., Rocheleau G., Roden M., Sampson M.J., Saxena R., Shields B.M., Shrader P., Sigurdsson G., Sparso T., Strassburger K., Stringham H.M., Sun Q., Swift A.J., Thorand B., Tichet J., Tuomi T., van Dam R.M., van Haeften T.W., van Herpt T., van Vliet-Ostaptchouk J.V., Walters G.B., Weedon M.N., Wijmenga C., Witteman J., Bergman R.N., Cauchi S., Collins F.S., Gloyn A.L., Gyllensten U., Hansen T., Hide W.A., Hitman G.A., Hofman A., Hunter D.J., Hveem K., Laakso M., Mohlke K.L., Morris A.D., Palmer C.N., Pramstaller P.P., Rudan I., Sijbrands E., Stein L.D., Tuomilehto J., Uitterlinden A., Walker M., Wareham N.J., Watanabe R.M., Abecasis G.R., Boehm B.O., Campbell H., Daly M.J., Hattersley A.T., Hu F.B., Meigs J.B., Pankow J.S., Pedersen O., Wichmann H.E., Barroso I., Florez J.C., Frayling T.M., Groop L., Sladek R., Thorsteinsdottir U., Wilson J.F., Illig T., Froguel P., van Duijn C.M., Stefansson K., Altshuler D., Boehnke M., McCarthy M.I., M.investigators, G.Consortium Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 2010, 42:579-589.
252. Fukuda H., Imamura M., Tanaka Y., Iwata M., Hirose H., Kaku K., Maegawa H., Watada H., Tobe K., Kashiwagi A., Kawamori R., Maeda S. A single nucleotide polymorphism within DUSP9 is associated with susceptibility to type 2 diabetes in a Japanese population. PLoS One 2012, 7:e46263.
253. Georgescu M.M. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2011, 1:1170-1177.
254. Zhang S., Yu D. PI(3)king apart PTEN's role in cancer. Clin. Cancer Res. 2010, 16:4325-4330.
255. Leslie N.R., Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol. Sci. 2010, 32:131-140.
256. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
257. Leslie N.R., Maccario H., Spinelli L., Davidson L. The significance of PTEN's protein phosphatase activity. Adv. Enzyme Regul. 2009, 49:190-196.
258. Zhang X.C., Piccini A., Myers M.P., Van Aelst L., Tonks N.K. Functional analysis of the protein phosphatase activity of PTEN. Biochem. J. 2012, 444(3):457-464. (PMID: 22413754).
259. Gu T., Zhang Z., Wang J., Guo J., Shen W.H., Yin Y. CREB is a novel nuclear target of PTEN phosphatase. Cancer Res. 2011, 71:2821-2825.
260. He X., Saji M., Radhakrishnan D., Romigh T., Ngeow J., Yu Q., Wang Y., Ringel M.D., Eng C. PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden Syndrome. J. Clin. Endocrinol. Metab. 2012, 97:E2179-E2187.
261. Orloff M.S., Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008, 27:5387-5397.
262. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. 2011, 11:289-301.
263. Hobert J.A., Eng C. PTEN hamartoma tumor syndrome: an overview. Genet. Med. 2009, 11:687-694.
264. Blumenthal G.M., Dennis P.A. PTEN hamartoma tumor syndromes. Eur. J. Hum. Genet. 2008, 16:1289-1300.
265. Tan M.H., Mester J., Peterson C., Yang Y., Chen J.L., Rybicki L.A., Milas K., Pederson H., Remzi B., Orloff M.S., Eng C. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am. J. Hum. Genet. 2011, 88:42-56.
266. Pal A., Barber T.M., Van de Bunt M., Rudge S.A., Zhang Q., Lachlan K.L., Cooper N.S., Linden H., Levy J.C., Wakelam M.J., Walker L., Karpe F., Gloyn A.L. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N. Engl. J. Med. 2012, 367:1002-1011.
267. Rodriguez-Escudero I., Oliver M.D., Andres-Pons A., Molina M., Cid V.J., Pulido R. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum. Mol. Genet. 2011, 20:4132-4142.
268. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 1998, 8:1169-1178.
269. Kishimoto H., Hamada K., Saunders M., Backman S., Sasaki T., Nakano T., Mak T.W., Suzuki A. Physiological functions of Pten in mouse tissues. Cell Struct. Funct. 2003, 28:11-21.
270. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat. Rev. 2011, 11:503-511.
271. Yeager N., Klein-Szanto A., Kimura S., Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res. 2007, 67:959-966.
272. Kwon C.H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W., Li Y., Baker S.J., Parada L.F. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388.
273. Endersby R., Baker S.J. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008, 27:5416-5430.
274. Mester J.L., Tilot A.K., Rybicki L.A., Frazier T.W., Eng C. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur. J. Hum. Genet. 2011, 19:763-768.
275. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000, 60:3605-3611.
276. Andres-Pons A., Rodriguez-Escudero I., Gil A., Blanco A., Vega A., Molina M., Pulido R., Cid V.J. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. Cancer Res. 2007, 67:9731-9739.
277. Carracedo A., Alimonti A., Pandolfi P.P. PTEN level in tumor suppression: how much is too little?. Cancer Res. 2011, 71:629-633.
278. Garcia-Cao I., Song M.S., Hobbs R.M., Laurent G., Giorgi C., de Boer V.C., Anastasiou D., Ito K., Sasaki A.T., Rameh L., Carracedo A., Vander Heiden M.G., Cantley L.C., Pinton P., Haigis M.C., Pandolfi P.P. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012, 149:49-62.
279. Ortega-Molina A., Efeyan A., Lopez-Guadamillas E., Munoz-Martin M., Gomez-Lopez G., Canamero M., Mulero F., Pastor J., Martinez S., Romanos E., Mar Gonzalez-Barroso M., Rial E., Valverde A.M., Bischoff J.R., Serrano M. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab. 2012, 15:382-394.
280. Ding J., Gao Y., Liu R., Xu F., Liu H. Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 2011, 30:229-234.
281. Heikkinen T., Greco D., Pelttari L.M., Tommiska J., Vahteristo P., Heikkila P., Blomqvist C., Aittomaki K., Nevanlinna H. Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res. 2011, 13:R130.
282. Ma J., Zhang J., Ning T., Chen Z., Xu C. Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma. J. Hum. Genet. 2012, 57:261-264.
283. Canbay E., Kahraman O.T., Bugra D., Caykara B., Seyhan M.F., Bulut T., Yamaner S., Ozturk O. Association between PTEN IVS4 polymorphism and development of colorectal cancer in a Turkish population. Expert Opin. Ther. Targets 2013, 17:1-6.
284. Ozturk O., Canbay E., Kahraman O.T., Fatih Seyhan M., Aydogan F., Celik V., Uras C. HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer. Mol. Biol. Rep. 2013, 40(2):1813-1818. (PMID: 23086302).
285. Hosgood H.D., Menashe I., He X., Chanock S., Lan Q. PTEN identified as important risk factor of chronic obstructive pulmonary disease. Respir. Med. 2009, 103:1866-1870.
286. Yuan M., Wang X., Zhan Q., Duan X., Yang Q., Xia J. Association of PTEN genetic polymorphisms with atherosclerotic cerebral infarction in the Han Chinese population. J. Clin. Neurosci. 2012, 19:1641-1645.
287. Bessette D.C., Qiu D., Pallen C.J. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008, 27:231-252.
288. Guzinska-Ustymowicz K., Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med. Chem. 2011, 11:99-108.
289. Rios P., Li X., Kohn M. Molecular mechanisms of the PRL phosphatases. FEBS J. 2013, 280(2):505-524. (PMID: 22413991).
290. Fiordalisi J.J., Keller P.J., Cox A.D. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006, 66:3153-3161.
291. Achiwa H., Lazo J.S. PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res. 2007, 67:643-650.
292. Werner S.R., Lee P.A., DeCamp M.W., Crowell D.N., Randall S.K., Crowell P.L. Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases. Cancer Lett. 2003, 202:201-211.
293. Zuo L., Zhang C.K., Wang F., Li C.S., Zhao H., Lu L., Zhang X.Y., Lu L., Zhang H., Zhang F., Krystal J.H., Luo X. A novel, functional and replicable risk gene region for alcohol dependence identified by genome-wide association study. PLoS One 2011, 6:e26726.
294. Mulligan M.K., Ponomarev I., Hitzemann R.J., Belknap J.K., Tabakoff B., Harris R.A., Crabbe J.C., Blednov Y.A., Grahame N.J., Phillips T.J., Finn D.A., Hoffman P.L., Iyer V.R., Koob G.F., Bergeson S.E. Toward understanding the genetics of alcohol drinking through transcriptome meta-analysis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6368-6373.
295. Lorenzo O., Urbe S., Clague M.J. Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and endosome related functions. J. Cell Sci. 2006, 119:2953-2959.
296. Hnia K., Vaccari I., Bolino A., Laporte J. Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology. Trends Mol. Med. 2012, 18:317-327.
297. Mruk D.D., Cheng C.Y. The myotubularin family of lipid phosphatases in disease and in spermatogenesis. Biochem. J. 2011, 433:253-262.
298. Robinson F.L., Dixon J.E. Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol. 2006, 16:403-412.
299. Berger P., Tersar K., Ballmer-Hofer K., Suter U. The CMT4B disease-causing proteins MTMR2 and MTMR13/SBF2 regulate AKT signaling. J. Cell. Mol. Med. 2009, 15:307-315.
300. Razidlo G.L., Katafiasz D., Taylor G.S. Myotubularin regulates Akt-dependent survival signaling via phosphatidylinositol 3-phosphate. J. Biol. Chem. 2011, 286:20005-20019.
301. Biancalana V., Caron O., Gallati S., Baas F., Kress W., Novelli G., D'Apice M.R., Lagier-Tourenne C., Buj-Bello A., Romero N.B., Mandel J.L. Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. Hum. Genet. 2003, 112:135-142.
302. Herman G.E., Kopacz K., Zhao W., Mills P.L., Metzenberg A., Das S. Characterization of mutations in fifty North American patients with X-linked myotubular myopathy. Hum. Mutat. 2002, 19:114-121.
303. Laporte J., Biancalana V., Tanner S.M., Kress W., Schneider V., Wallgren-Pettersson C., Herger F., Buj-Bello A., Blondeau F., Liechti-Gallati S., Mandel J.L. MTM1 mutations in X-linked myotubular myopathy. Hum. Mutat. 2000, 15:393-409.
304. Laporte J., Hu L.J., Kretz C., Mandel J.L., Kioschis P., Coy J.F., Klauck S.M., Poustka A., Dahl N. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 1996, 13:175-182.
305. Romero N.B. Centronuclear myopathies: a widening concept. Neuromuscul. Disord. 2010, 20:223-228.
306. Al-Qusairi L., Weiss N., Toussaint A., Berbey C., Messaddeq N., Kretz C., Sanoudou D., Beggs A.H., Allard B., Mandel J.L., Laporte J., Jacquemond V., Buj-Bello A. T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18763-18768.
307. Buj-Bello A., Laugel V., Messaddeq N., Zahreddine H., Laporte J., Pellissier J.F., Mandel J.L. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15060-15065.
308. Pierson C.R., Dulin-Smith A.N., Durban A.N., Marshall M.L., Marshall J.T., Snyder A.D., Naiyer N., Gladman J.T., Chandler D.S., Lawlor M.W., Buj-Bello A., Dowling J.J., Beggs A.H. Modeling the human MTM1 p.R69C mutation in murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy phenotype. Hum. Mol. Genet. 2012, 21:811-825.
309. Beggs A.H., Bohm J., Snead E., Kozlowski M., Maurer M., Minor K., Childers M.K., Taylor S.M., Hitte C., Mickelson J.R., Guo L.T., Mizisin A.P., Buj-Bello A., Tiret L., Laporte J., Shelton G.D. MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14697-14702.
310. Dowling J.J., Vreede A.P., Low S.E., Gibbs E.M., Kuwada J.Y., Bonnemann C.G., Feldman E.L. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet. 2009, 5:e1000372.
311. Hnia K., Tronchere H., Tomczak K.K., Amoasii L., Schultz P., Beggs A.H., Payrastre B., Mandel J.L., Laporte J. Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle. J. Clin. Invest. 2011, 121:70-85.
312. Amoasii L., Bertazzi D.L., Tronchere H., Hnia K., Chicanne G., Rinaldi B., Cowling B.S., Ferry A., Klaholz B., Payrastre B., Laporte J., Friant S. Phosphatase-dead myotubularin ameliorates X-linked centronuclear myopathy phenotypes in mice. PLoS Genet. 2012, 8:e1002965.
313. Gibbs E.M., Feldman E.L., Dowling J.J. The role of MTMR14 in autophagy and in muscle disease. Autophagy 2010, 6:819-820.
314. Tosch V., Rohde H.M., Tronchere H., Zanoteli E., Monroy N., Kretz C., Dondaine N., Payrastre B., Mandel J.L., Laporte J. A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. Hum. Mol. Genet. 2006, 15:3098-3106.
315. Vergne I., Deretic V. The role of PI3P phosphatases in the regulation of autophagy. FEBS Lett. 2010, 584:1313-1318.
316. Romero-Suarez S., Shen J., Brotto L., Hall T., Mo C., Valdivia H.H., Andresen J., Wacker M., Nosek T.M., Qu C.K., Brotto M. Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with age and its loss accelerates skeletal muscle aging process by altering calcium homeostasis. Aging (Albany NY) 2010, 2:504-513.
317. Shen J., Yu W.M., Brotto M., Scherman J.A., Guo C., Stoddard C., Nosek T.M., Valdivia H.H., Qu C.K. Deficiency of MIP/MTMR14 phosphatase induces a muscle disorder by disrupting Ca(2+) homeostasis. Nat. Cell Biol. 2009, 11:769-776.
318. Dowling J.J., Low S.E., Busta A.S., Feldman E.L. Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. Hum. Mol. Genet. 2010, 19:2668-2681.
319. Jaradeh S.S. Hereditary neuropathies. J. Clin. Neuromuscul. Dis. 2003, 5:72-80.
320. Kabzinska D., Hausmanowa-Petrusewicz I., Kochanski A. Charcot-Marie-Tooth disorders with an autosomal recessive mode of inheritance. Clin. Neuropathol. 2008, 27:1-12.
321. Previtali S.C., Zerega B., Sherman D.L., Brophy P.J., Dina G., King R.H., Salih M.M., Feltri L., Quattrini A., Ravazzolo R., Wrabetz L., Monaco A.P., Bolino A. Myotubularin-related 2 protein phosphatase and neurofilament light chain protein, both mutated in CMT neuropathies, interact in peripheral nerve. Hum. Mol. Genet. 2003, 12:1713-1723.
322. Bolis A., Zordan P., Coviello S., Bolino A. Myotubularin-related (MTMR) phospholipid phosphatase proteins in the peripheral nervous system. Mol. Neurobiol. 2007, 35:308-316.
323. Bolino A., Muglia M., Conforti F.L., LeGuern E., Salih M.A., Georgiou D.M., Christodoulou K., Hausmanowa-Petrusewicz I., Mandich P., Schenone A., Gambardella A., Bono F., Quattrone A., Devoto M., Monaco A.P. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat. Genet. 2000, 25:17-19.
324. Senderek J., Bergmann C., Weber S., Ketelsen U.P., Schorle H., Rudnik-Schoneborn S., Buttner R., Buchheim E., Zerres K. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum. Mol. Genet. 2003, 12:349-356.
325. Berger P., Bonneick S., Willi S., Wymann M., Suter U. Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1. Hum. Mol. Genet. 2002, 11:1569-1579.
326. Tersar K., Boentert M., Berger P., Bonneick S., Wessig C., Toyka K.V., Young P., Suter U. Mtmr13/Sbf2-deficient mice: an animal model for CMT4B2. Hum. Mol. Genet. 2007, 16:2991-3001.
327. Bonneick S., Boentert M., Berger P., Atanasoski S., Mantei N., Wessig C., Toyka K.V., Young P., Suter U. An animal model for Charcot-Marie-Tooth disease type 4B1. Hum. Mol. Genet. 2005, 14:3685-3695.
328. Bolis A., Coviello S., Bussini S., Dina G., Pardini C., Previtali S.C., Malaguti M., Morana P., Del Carro U., Feltri M.L., Quattrini A., Wrabetz L., Bolino A. Loss of Mtmr2 phosphatase in Schwann cells but not in motor neurons causes Charcot-Marie-Tooth type 4B1 neuropathy with myelin outfoldings. J. Neurosci. 2005, 25:8567-8577.
329. Bolino A., Bolis A., Previtali S.C., Dina G., Bussini S., Dati G., Amadio S., Del Carro U., Mruk D.D., Feltri M.L., Cheng C.Y., Quattrini A., Wrabetz L. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J. Cell Biol. 2004, 167:711-721.
330. Lei S.F., Tan L.J., Liu X.G., Wang L., Yan H., Guo Y.F., Liu Y.Z., Xiong D.H., Li J., Yang T.L., Chen X.D., Guo Y., Deng F.Y., Zhang Y.P., Zhu X.Z., Levy S., Papasian C.J., Hamilton J.J., Recker R.R., Deng H.W. Genome-wide association study identifies two novel loci containing FLNB and SBF2 genes underlying stature variation. Hum. Mol. Genet. 2009, 18:1661-1669.
331. Hu Z., Wu C., Shi Y., Guo H., Zhao X., Yin Z., Yang L., Dai J., Hu L., Tan W., Li Z., Deng Q., Wang J., Wu W., Jin G., Jiang Y., Yu D., Zhou G., Chen H., Guan P., Chen Y., Shu Y., Xu L., Liu X., Liu L., Xu P., Han B., Bai C., Zhao Y., Zhang H., Yan Y., Ma H., Chen J., Chu M., Lu F., Zhang Z., Chen F., Wang X., Jin L., Lu J., Zhou B., Lu D., Wu T., Lin D., Shen H. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat. Genet. 2011, 43:792-796.
332. Lin Y., Nie Y., Zhao J., Chen X., Ye M., Li Y., Du Y., Cao J., Shen B., Li Y. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis 2012, 33(12):2377-2383. (PMID: 22971574).
333. Henderson P., van Limbergen J.E., Wilson D.C., Satsangi J., Russell R.K. Genetics of childhood-onset inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17:346-361.
334. Sanchez-Juan P., Bishop M.T., Aulchenko Y.S., Brandel J.P., Rivadeneira F., Struchalin M., Lambert J.C., Amouyel P., Combarros O., Sainz J., Carracedo A., Uitterlinden A.G., Hofman A., Zerr I., Kretzschmar H.A., Laplanche J.L., Knight R.S., Will R.G., van Duijn C.M. Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiol. Aging 2012, 33(7):1487.e21-8. (PMID: 22137330).
335. Hotta K., Kitamoto T., Kitamoto A., Mizusawa S., Matsuo T., Nakata Y., Kamohara S., Miyatake N., Kotani K., Komatsu R., Itoh N., Mineo I., Wada J., Yoneda M., Nakajima A., Funahashi T., Miyazaki S., Tokunaga K., Masuzaki H., Ueno T., Hamaguchi K., Tanaka K., Yamada K., Hanafusa T., Oikawa S., Yoshimatsu H., Sakata T., Matsuzawa Y., Nakao K., Sekine A. Association of variations in the FTO, SCG3 and MTMR9 genes with metabolic syndrome in a Japanese population. J. Hum. Genet. 2011, 56:647-651.
336. Yanagiya T., Tanabe A., Iida A., Saito S., Sekine A., Takahashi A., Tsunoda T., Kamohara S., Nakata Y., Kotani K., Komatsu R., Itoh N., Mineo I., Wada J., Masuzaki H., Yoneda M., Nakajima A., Miyazaki S., Tokunaga K., Kawamoto M., Funahashi T., Hamaguchi K., Tanaka K., Yamada K., Hanafusa T., Oikawa S., Yoshimatsu H., Nakao K., Sakata T., Matsuzawa Y., Kamatani N., Nakamura Y., Hotta K. Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. Hum. Mol. Genet. 2007, 16:3017-3026.
337. Gentry M.S., Dixon J.E., Worby C.A. Lafora disease: insights into neurodegeneration from plant metabolism. Trends Biochem. Sci. 2009, 34:628-639.
338. Ramachandran N., Girard J.M., Turnbull J., Minassian B.A. The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia 2009, 50(Suppl. 5):29-36.
339. Roma-Mateo C., Sanz P., Gentry M.S. Deciphering the role of malin in the lafora progressive myoclonus epilepsy. IUBMB Life 2012, 64:801-808.
340. Singh S., Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum. Mutat. 2009, 30:715-723.
341. Serratosa J.M., Gomez-Garre P., Gallardo M.E., Anta B., de Bernabe D.B., Lindhout D., Augustijn P.B., Tassinari C.A., Malafosse R.M., Topcu M., Grid D., Dravet C., Berkovic S.F., de Cordoba S.R. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum. Mol. Genet. 1999, 8:345-352.
342. Minassian B.A., Lee J.R., Herbrick J.A., Huizenga J., Soder S., Mungall A.J., Dunham I., Gardner R., Fong C.Y., Carpenter S., Jardim L., Satishchandra P., Andermann E., Snead O.C., Lopes-Cendes I., Tsui L.C., Delgado-Escueta A.V., Rouleau G.A., Scherer S.W. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 1998, 20:171-174.
343. Chan E.M., Young E.J., Ianzano L., Munteanu I., Zhao X., Christopoulos C.C., Avanzini G., Elia M., Ackerley C.A., Jovic N.J., Bohlega S., Andermann E., Rouleau G.A., Delgado-Escueta A.V., Minassian B.A., Scherer S.W. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 2003, 35:125-127.
344. Puri R., Suzuki T., Yamakawa K., Ganesh S. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J. Biol. Chem. 2009, 284:22657-22663.
345. Tagliabracci V.S., Turnbull J., Wang W., Girard J.M., Zhao X., Skurat A.V., Delgado-Escueta A.V., Minassian B.A., Depaoli-Roach A.A., Roach P.J. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19262-19266.
346. Gentry M.S., Roma-Mateo C., Sanz P. Laforin, a protein with many faces: glucan phosphatase, adapter protein, and others. FEBS J. 2013, 280(2):525-537. (PMID: 22364389).
347. Knecht E., Aguado C., Sarkar S., Korolchuk V.I., Criado-Garcia O., Vernia S., Boya P., Sanz P., Rodriguez de Cordoba S., Rubinsztein D.C. Impaired autophagy in Lafora disease. Autophagy 2010, 6:991-993.
348. Aguado C., Sarkar S., Korolchuk V.I., Criado O., Vernia S., Boya P., Sanz P., de Cordoba S.R., Knecht E., Rubinsztein D.C. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum. Mol. Genet. 2010, 19:2867-2876.
349. Vernia S., Heredia M., Criado O., Rodriguez de Cordoba S., Garcia-Roves P.M., Cansell C., Denis R., Luquet S., Foufelle F., Ferre P., Sanz P. Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. Hum. Mol. Genet. 2011, 20:2571-2584.
350. DePaoli-Roach A.A., Segvich D.M., Meyer C.M., Rahimi Y., Worby C.A., Gentry M.S., Roach P.J. Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity. Hum. Mol. Genet. 2012, 21:1604-1610.
351. Wang Y., Liu Y., Wu C., McNally B., Liu Y., Zheng P. Laforin confers cancer resistance to energy deprivation-induced apoptosis. Cancer Res. 2008, 68:4039-4044.
352. Wang Y., Liu Y., Wu C., Zhang H., Zheng X., Zheng Z., Geiger T.L., Nuovo G.J., Liu Y., Zheng P. Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 2006, 10:179-190.
353. Liu R., Wang L., Chen C., Liu Y., Zhou P., Wang Y., Wang X., Turnbull J., Minassian B.A., Zheng P. Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms. Mol. Cell. Biol. 2008, 28:7236-7244.
354. Ganesh S., Delgado-Escueta A.V., Sakamoto T., Avila M.R., Machado-Salas J., Hoshii Y., Akagi T., Gomi H., Suzuki T., Amano K., Agarwala K.L., Hasegawa Y., Bai D.S., Ishihara T., Hashikawa T., Itohara S., Cornford E.M., Niki H., Yamakawa K. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 2002, 11:1251-1262.
355. Tagliabracci V.S., Girard J.M., Segvich D., Meyer C., Turnbull J., Zhao X., Minassian B.A., Depaoli-Roach A.A., Roach P.J. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J. Biol. Chem. 2008, 283:33816-33825.
356. Vernia S., Rubio T., Heredia M., Rodriguez de Cordoba S., Sanz P. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PLoS One 2009, 4:e5907.
357. Gomez-Garre P., Sanz Y., Rodriguez De Cordoba S.R., Serratosa J.M. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. Eur. J. Hum. Genet. 2000, 8:946-954.
358. Gomez-Abad C., Afawi Z., Korczyn A.D., Misk A., Shalev S.A., Spiegel R., Lerman-Sagie T., Lev D., Kron K.L., Gomez-Garre P., Serratosa J.M., Berkovic S.F. Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation. Epilepsia 2007, 48:1011-1014.
359. Dubey D., Ganesh S. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum. Mol. Genet. 2008, 17:3010-3020.
360. Dubey D., Parihar R., Ganesh S. Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy. Genomics 2012, 99:36-43.
361. Ganesh S., Shoda K., Amano K., Uchiyama A., Kumada S., Moriyama N., Hirose S., Yamakawa K. Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene. Mol. Cell. Probes 2001, 15:281-289.
362. Jemc J., Rebay I. The eyes absent family of phosphotyrosine phosphatases: properties and roles in developmental regulation of transcription. Annu. Rev. Biochem. 2007, 76:513-538.
363. Okabe Y., Sano T., Nagata S. Regulation of the innate immune response by threonine-phosphatase of eyes absent. Nature 2009, 460:520-524.
364. Zhang L., Yang N., Huang J., Buckanovich R.J., Liang S., Barchetti A., Vezzani C., O'Brien-Jenkins A., Wang J., Ward M.R., Courreges M.C., Fracchioli S., Medina A., Katsaros D., Weber B.L., Coukos G. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res. 2005, 65:925-932.
365. Pandey R.N., Rani R., Yeo E.J., Spencer M., Hu S., Lang R.A., Hegde R.S. The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene 2010, 29:3715-3722.
366. Farabaugh S.M., Micalizzi D.S., Jedlicka P., Zhao R., Ford H.L. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2012, 31:552-562.
367. Tadjuidje E., Wang T.S., Pandey R.N., Sumanas S., Lang R.A., Hegde R.S. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. PLoS One 2012, 7:e34806.
368. Cook P.J., Ju B.G., Telese F., Wang X., Glass C.K., Rosenfeld M.G. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009, 458:591-596.
369. Krishnan N., Jeong D.G., Jung S.K., Ryu S.E., Xiao A., Allis C.D., Kim S.J., Tonks N.K. Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent. J. Biol. Chem. 2009, 284:16066-16070.
370. Rayapureddi J.P., Hegde R.S. Branchio-oto-renal syndrome associated mutations in Eyes Absent 1 result in loss of phosphatase activity. FEBS Lett. 2006, 580:3853-3859.
371. Kimberling W.J., Borsa N., Smith R.J. Hearing loss disorders associated with renal disease. Adv. Otorhinolaryngol. 2011, 70:75-83.
372. Orten D.J., Fischer S.M., Sorensen J.L., Radhakrishna U., Cremers C.W., Marres H.A., Van Camp G., Welch K.O., Smith R.J., Kimberling W.J. Branchio-oto-renal syndrome (BOR): novel mutations in the EYA1 gene, and a review of the mutational genetics of BOR. Hum. Mutat. 2008, 29:537-544.
373. Rickard S., Parker M., van't Hoff W., Barnicoat A., Russell-Eggitt I., Winter R.M., Bitner-Glindzicz M. Oto-facio-cervical (OFC) syndrome is a contiguous gene deletion syndrome involving EYA1: molecular analysis confirms allelism with BOR syndrome and further narrows the Duane syndrome critical region to 1cM. Hum. Genet. 2001, 108:398-403.
374. Landgraf K., Bollig F., Trowe M.O., Besenbeck B., Ebert C., Kruspe D., Kispert A., Hanel F., Englert C. Sipl1 and Rbck1 are novel Eya1-binding proteins with a role in craniofacial development. Mol. Cell. Biol. 2010, 30:5764-5775.
375. van Eerde A.M., Duran K., van Riel E., de Kovel C.G., Koeleman B.P., Knoers N.V., Renkema K.Y., van der Horst H.J., Bokenkamp A., van Hagen J.M., van den Berg L.H., Wolffenbuttel K.P., van den Hoek J., Feitz W.F., de Jong T.P., Giltay J.C., Wijmenga C. Genes in the ureteric budding pathway: association study on vesico-ureteral reflux patients. PLoS One 2012, 7:e31327.
376. Wayne S., Robertson N.G., DeClau F., Chen N., Verhoeven K., Prasad S., Tranebjarg L., Morton C.C., Ryan A.F., Van Camp G., Smith R.J. Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus. Hum. Mol. Genet. 2001, 10:195-200.
377. Hildebrand M.S., Coman D., Yang T., Gardner R.J., Rose E., Smith R.J., Bahlo M., Dahl H.H. A novel splice site mutation in EYA4 causes DFNA10 hearing loss. Am. J. Med. Genet. 2007, 143A:1599-1604.
378. Dutrannoy V., Klopocki E., Wei R., Bommer C., Mundlos S., Graul-Neumann L.M., Trimborn M. De novo 9Mb deletion of 6q23.2q24.1 disrupting the gene EYA4 in a patient with sensorineural hearing loss, cardiac malformation, and mental retardation. Eur. J. Med. Genet. 2009, 52:450-453.
379. Depreux F.F., Darrow K., Conner D.A., Eavey R.D., Liberman M.C., Seidman C.E., Seidman J.G. Eya4-deficient mice are a model for heritable otitis media. J. Clin. Invest. 2008, 118:651-658.
380. Schonberger J., Levy H., Grunig E., Sangwatanaroj S., Fatkin D., MacRae C., Stacker H., Halpin C., Eavey R., Philbin E.F., Katus H., Seidman J.G., Seidman C.E. Dilated cardiomyopathy and sensorineural hearing loss: a heritable syndrome that maps to 6q23-24. Circulation 2000, 101:1812-1818.
381. Schonberger J., Wang L., Shin J.T., Kim S.D., Depreux F.F., Zhu H., Zon L., Pizard A., Kim J.B., Macrae C.A., Mungall A.J., Seidman J.G., Seidman C.E. Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat. Genet. 2005, 37:418-422.
382. Makishima T., Madeo A.C., Brewer C.C., Zalewski C.K., Butman J.A., Sachdev V., Arai A.E., Holbrook B.M., Rosing D.R., Griffith A.J. Nonsyndromic hearing loss DFNA10 and a novel mutation of EYA4: evidence for correlation of normal cardiac phenotype with truncating mutations of the Eya domain. Am. J. Med. Genet. 2007, 143A:1592-1598.
383. Plant D., Bowes J., Potter C., Hyrich K.L., Morgan A.W., Wilson A.G., Isaacs J.D., Barton A. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011, 63:645-653. C. Wellcome Trust Case Control, R. British Society for Rheumatology BiologicsR. British Society for Rheumatology Biologics.
384. Abe Y., Oka A., Mizuguchi M., Igarashi T., Ishikawa S., Aburatani H., Yokoyama S., Asahara H., Nagao K., Yamada M., Miyashita T. EYA4, deleted in a case with middle interhemispheric variant of holoprosencephaly, interacts with SIX3 both physically and functionally. Hum. Mutat. 2009, 30:E946-E955.
385. He R., Zeng L.F., He Y., Zhang S., Zhang Z.Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J. 2013, 280(2):731-750. (PMID: 22816879).
386. Wu Y., Feng X., Jin Y., Wu Z., Hankey W., Paisie C., Li L., Liu F., Barsky S.H., Zhang W., Ganju R., Zou X. A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation. Cancer Prev. Res. 2010, 3:818-828.
387. Liu G. Technology evaluation: ISIS-113715, Isis. Curr. Opin. Mol. Ther. 2004, 6:331-336.
388. Aartsma-Rus A., den Dunnen J.T., van Ommen G.J. New insights in gene-derived therapy: the example of Duchenne muscular dystrophy. Ann. N. Y. Acad. Sci. 2010, 1214:199-212.
389. Hu S., Huang M., Li Z., Jia F., Ghosh Z., Lijkwan M.A., Fasanaro P., Sun N., Wang X., Martelli F., Robbins R.C., Wu J.C. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122:S124-S131.
390. Tay Y., Kats L., Salmena L., Weiss D., Tan S.M., Ala U., Karreth F., Poliseno L., Provero P., Di Cunto F., Lieberman J., Rigoutsos I., Pandolfi P.P. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357.